JP2017507954A5 - - Google Patents

Info

Publication number

JP2017507954A5

JP2017507954A5 JP2016554353A JP2016554353A JP2017507954A5 JP 2017507954 A5 JP2017507954 A5 JP 2017507954A5 JP 2016554353 A JP2016554353 A JP 2016554353A JP 2016554353 A JP2016554353 A JP 2016554353A JP 2017507954 A5 JP2017507954 A5 JP 2017507954A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

antibody

seq

composition according

amino acid

Prior art date

2015-02-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 20
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 20
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 20
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 8
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 6
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 6
• 210000004027 cell Anatomy 0.000 claims description 6
• 238000000338 in vitro Methods 0.000 claims description 6
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 6
• 229960004528 vincristine Drugs 0.000 claims description 6
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims description 4
• 238000009093 first-line therapy Methods 0.000 claims description 4
• 150000004676 glycans Chemical group 0.000 claims description 4
• 229940043355 kinase inhibitor Drugs 0.000 claims description 4
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
• 238000001959 radiotherapy Methods 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 239000003840 Bafetinib Substances 0.000 claims description 2
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 2
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 2
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
• 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
• 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 2
• 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 2
• 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 2
• 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 2
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 2
• GCIKSSRWRFVXBI-UHFFFAOYSA-N N-[4-[[4-(4-methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 GCIKSSRWRFVXBI-UHFFFAOYSA-N 0.000 claims description 2
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
• 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 claims description 2
• 201000011184 adult acute lymphocytic leukemia Diseases 0.000 claims description 2
• 230000006907 apoptotic process Effects 0.000 claims description 2
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
• 229950002365 bafetinib Drugs 0.000 claims description 2
• ZGBAJMQHJDFTQJ-DEOSSOPVSA-N bafetinib Chemical compound C1[C@@H](N(C)C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=NC=3)C(C)=CC=2)C=C1C(F)(F)F ZGBAJMQHJDFTQJ-DEOSSOPVSA-N 0.000 claims description 2
• 238000004820 blood count Methods 0.000 claims description 2
• 229960003736 bosutinib Drugs 0.000 claims description 2
• UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 2
• 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 claims description 2
• 229960002448 dasatinib Drugs 0.000 claims description 2
• 230000000694 effects Effects 0.000 claims description 2
• 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 2
• 102000052645 human CD38 Human genes 0.000 claims description 2
• 229960001507 ibrutinib Drugs 0.000 claims description 2
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 2
• 229960002411 imatinib Drugs 0.000 claims description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
• 210000000265 leukocyte Anatomy 0.000 claims description 2
• 229960001346 nilotinib Drugs 0.000 claims description 2
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 2
• 210000004214 philadelphia chromosome Anatomy 0.000 claims description 2
• 229960001131 ponatinib Drugs 0.000 claims description 2
• PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 2
• 229950009919 saracatinib Drugs 0.000 claims description 2
• OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 claims description 2
• 238000006467 substitution reaction Methods 0.000 claims description 2
• 229950000185 tozasertib Drugs 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 21
• 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 3
• 239000003814 drug Substances 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 238000000034 method Methods 0.000 description 21
• 241000699670 Mus sp. Species 0.000 description 2
• 229960002204 daratumumab Drugs 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1